Millennium UDT Update
Expanding Our Novel Psychoactive Substances Test Offerings
SAN DIEGO, Calif. – August 15, 2022 – We are pleased to announce that, as of Monday, August 15, 2022, we are updating our definitive urine drug testing (UDT) menu to expand our novel psychoactive substances test offerings, based on surveillance data from the DEA and Center for Forensic Science Research and Education (CFSRE). Additionally, we have updated our fentanyl analogues offerings to add the most identified fentanyl analogue other than illicit fentanyl itself, para-fluororfentanyl.1,2 These drugs are not typically detected by presumptive, immunoassay point-of-care or desktop analyzer drug tests,3 and include:
Novel Illicit Benzodiazepines
- Clonazolam (tested by its metabolite, 8-aminoclonazolam)
- Etizolam
- Alpha-hydroxyetizolam
- Flualprazolam
- Flubromazolam
Novel Illicit Opioids
- 2-methyl-AP-237
- Brorphine
- Metonitazene
Updated Fentanyl Analogues Offerings
- Para-fluorofentanyl (NEW)
- Fentanyl
- Norfentanyl
- 4-ANPP
- Acetyl fentanyl
- Acetyl norfentanyl
- Acrylfentanyl
- Carfentanil
About Millennium Health
Millennium Health is an accredited specialty laboratory with over a decade of experience delivering timely, accurate, clinically-actionable information through our nationwide medication monitoring and drug testing services. Clinical drug testing is used in various healthcare settings to obtain objective information about patients’ recent use of prescription medications and illicit drugs. Processing hundreds of thousands of specimens each year allows us to provide real-time analytics regarding emerging drug use trends, such as our studies published in JAMA and our most recent Millennium Health Signals Report™.
